TRCT
IGC icon

Tower Research Capital (TRC)’s IGC Pharma IGC Stock Holding History

Tower Research Capital (TRC)’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.54K Buy
21,049
+6,657
+46% +$1.85K ﹤0.01% 4109
2025
Q4 		$4.05K Buy
14,392
+4,599
+47% +$1.64K ﹤0.01% 4268
2025
Q3 		$4.08K Sell
9,793
-2,106
-18% -$801 ﹤0.01% 4407
2025
Q2 		$3.64K Sell
11,899
-1,454
-11% -$437 ﹤0.01% 4459
2025
Q1 		$3.81K Buy
13,353
+2,310
+21% +$729 ﹤0.01% 4346
2024
Q4 		$3.71K Buy
11,043
+547
+5% +$205 ﹤0.01% 4608
2024
Q3 		$4.48K Buy
10,496
+2,478
+31% +$993 ﹤0.01% 4532
2024
Q2 		$3.48K Sell
8,018
-5,636
-41% -$2.8K ﹤0.01% 4885
2024
Q1 		$5.46K Sell
13,654
-9,663
-41% -$3K ﹤0.01% 4539
2023
Q4 		$6.53K Buy
23,317
+1,982
+9% +$614 ﹤0.01% 4728
2023
Q3 		$7.66K Buy
21,335
+654
+3% +$234 ﹤0.01% 4446
2023
Q2 		$6.45K Sell
20,681
-114
-0.5% -$37 ﹤0.01% 4703
2023
Q1 		$7K Buy
20,795
+10,703
+106% +$4.01K ﹤0.01% 4741
2022
Q4 		$3K Buy
+10,092
New +$4.12K ﹤0.01% 5195
2022
Q2 		– Sell
-1,364
Closed -$1K – 6270
2022
Q1 		$1K Buy
1,364
+968
+244% +$940 ﹤0.01% 5804
2021
Q4 		$0 Buy
+396
New +$531 ﹤0.01% 6330
2021
Q1 		– Sell
-28,742
Closed -$45K – 5535
2020
Q4 		$45K Buy
28,742
+23,987
+504% +$35.4K ﹤0.01% 3213
2020
Q3 		$5K Buy
+4,755
New +$4.83K ﹤0.01% 4357
2015
Q3 		– Sell
-43
Closed – – 4349
2015
Q2 		$0 Hold
43
– – ﹤0.01% 4672
2015
Q1 		$0 Sell
43
-91
-68% -$49 ﹤0.01% 4643
2014
Q4 		$0 Hold
134
– – ﹤0.01% 4309
2014
Q3 		$0 Hold
134
– – ﹤0.01% 4621
2014
Q2 		$0 Buy
134
+27
+25% +$31 ﹤0.01% 4309
2014
Q1 		$0 Buy
107
+93
+664% +$81 ﹤0.01% 4659
2013
Q4 		$0 Buy
14
+7
+100% +$6 ﹤0.01% 4682
2013
Q3 		$0 Sell
7
-218
-97% -$272 ﹤0.01% 4670
2013
Q2 		$0 Buy
+225
New +$472 ﹤0.01% 3943

Other funds holding IGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LC
Lawood & Co Williamsport, Pennsylvania $148M AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tower Research Capital (TRC)'s IGC Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its IGC Pharma (IGC) stake by 46% in Q1 2026, buying an estimated $1.85K and bringing the position to 21,049 shares worth $5.54K. The position accounts for ﹤0.01% of the portfolio, ranked #4109.

Tower Research Capital (TRC) first reported a position in IGC in Q2 2013 and has held it in 27 quarters since. The position peaked at $45K in Q4 2020. 35 funds tracked by Wall St. Rank hold IGC as of Q1 2026.

  • Tower Research Capital (TRC) held 21,049 shares of IGC Pharma worth $5.54K as of Q1 2026.
  • Tower Research Capital (TRC) bought 6,657 IGC Pharma shares in Q1 2026, an estimated $1.85K.
  • IGC Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4109 holding.
  • Tower Research Capital (TRC) first reported a position in IGC Pharma in Q2 2013 and has held it in 27 quarters since.
  • Tower Research Capital (TRC)'s IGC Pharma position peaked at $45K in Q4 2020.
  • 35 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.